Recrystallized agglomerates of indomethacin by emulsion solvent diffusion (ESD) technique

International Journal of Pharma and Bio Sciences

Volumn 1, Issue 1, 2010, Pages

  Yadav, V B ^a   Yadav, A V ^b  

^a Department of Biopharmaceutics Government College of Pharmacy ^*  (India)

^b KRISHNA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Dissolution; Flowability; Indomethacin; Packability; Recrystallized agglomeratesdd; Solubility; Wettability

Indexed keywords

DICHLOROMETHANE; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; METHANOL; POVIDONE; WATER;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG DETERMINATION; DRUG SOLUBILITY; EMULSION SOLVENT DIFFUSION; FLOWABILITY; HYDROPHILICITY; MOLECULAR INTERACTION; PACKABILITY; PHYSICAL CHEMISTRY; PHYSICAL PHENOMENA; SOLVENT EFFECT; STRUCTURE ANALYSIS; SURFACE PROPERTY; WETTABILITY; X RAY DIFFRACTION;

EID: 82755187690     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lobenberg R, Amidon GL, Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm, 50: 3-12, (2000).
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev, 23: 3-25, (1997).
3. Testa B, Caldwell J, Prodrugs revisited: The "ad hoc" approach as a complement to ligand design. Med. Res. Rev, 16: 233-241, (1996).
4. Hancock BC, Zografi G, Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci, 86: 1-12, (1997).
5. Grau MJ, Kayser O, Muller RH, Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm, 196: 155-157, (2000).
6. Rasenack N, Hartenhauer H, Muller BW, Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm, 254: 137-145, (2003).
7. Mosharraf M, Nystrom C, The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int. J. Pharm, 122: 35-47, (1995).
8. Saleki-Gerhardt A, Ahlneck C, Zografi G, Assessment of disorder in crystalline solids. Int. J. Pharm, 101: 144, (1994).
9. Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K, Development of agglomerated crystals of Ascorbic acid by the spherical crystallization techniques. KONA, 20(3):251-61, (2002).
10. Goczo H, Szabo RP, HasznosNezdei M, Farkas B, Development of spherical crystals of Acetyl salicylic acid for direct tablet making.Chem.Pharm.Bull, 48(12):1877-81, (2000).
11. Kawashima Y, Okumura M, Takenaka H, Spherical crystallization: direct spherical agglomeration of Salicylic acid crystals during crystallization. Science, 216(4): 1127-28, (1982).
12. Goczo H, Szabo RP, Hasznos NM, Farkas B, Development of spherical crystals of Acetyl salicylic acid for direct tablet making. Chem.Pharm.Bull, 48(12): 1877-81, (2000).
13. Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K, Development of agglomerated crystals of Ascorbic acid by the spherical crystallization techniques. KONA, 20(3):251-61, (2002).
14. Lobenberg R, Amidon GL, Modern bioavailability, bioequivalence and biopharmaceutics classification system; new scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm, 50: 3 -12, (2000).
15. Hirasawa N, Ishise S, Miyata H, Danjo K, Physicochemical characterization and drug release studies of nilvadipine solid dispersions using water-insoluble polymer as a carrier. Drug Dev. Ind. Pharm, 29: 339-44, (2003).
16. Alsaidan SM, Alsughayer AA, Eshra AG. Improved dissolution rate of indomethacin by adsorbents. Drug Dev.Ind. Pharm, 24: 389-94, (1998).
17. United States Pharmacopoeia (USP) 30/NF 24.United States Pharmacopoeial Convention Inc.Rockville, USA, 2007, p. 242.
18. Ueda M, Nakamura Y, Makita H, Imasato Y, Kawashima Y. Particle design of Enoxacin by spherical crystallization technique II, Characteristics of agglomerated crystals. Chem Pharm Bull, 39: 1277-81, (1991).
19. Di Martino P, Barthélémy C, Piva F, Joiris E, Palmieri GF, Martelli S. Improved dissolution behavior of Fenbufen by spherical crystallization.Drug Dev Ind Pharm, 25:1073-81,(1999).